BioRestorative Therapies (NASDAQ:BRTX) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.30) by 4.92 percent. This is a 60 percent decrease over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $19.600 thousand which missed the analyst consensus estimate of $520.000 thousand by 96.23 percent. This is a 54.73 percent decrease over sales of $43.300 thousand the same period last year.